RBC Capital Upgrades Sarepta (SRPT) to Outperform; Becomes Attractive M&A Target
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
RBC Capital upgraded Sarepta Therapeutic (NASDAQ: SRPT) from Sector Perform to Outperform with a price target of $83.00 (from $5.00).
Analyst Simos Simeonidis commented, "In one of the most perplexing regulatory decisions in recent history, FDA has granted accelerated approval to Sarepta's eteplirsen. This decision, which may have a number of negative consequences for the review of rare disease drugs, is a major game-changer for SRPT, which we believe now becomes one of the most attractive M&A targets in biopharma, given both eteplirsen and its pipeline of exon-skipping compounds."
Shares of Sarepta Therapeutic closed at $28.15 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- RBC Capital Raises Price Target on Restaurant Brands (QSR) to $54
- Itron (ITRI): Raising PT Ahead Of Earnings - Baird
- FBR Capital Raises Price Target on HomeStreet (HMST) Following Record 3Q
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst PT Change, Rumors, Upgrades
Related EntitiesRBC Capital
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!